Arterial Hypertension and Cardiac Damage

go back to reference Agabiti-Rosei E, Giovannini E, Mancia G, et al. Arterial hypertension and cardiac pathology: diagnostic and therapeutic guidelines presented by the Joint Commission of the ANMCO-SIC-SIIA. Associazione Nazionale Medici Cardiologi Ospedalieri. Società Italiana di Cardiologia. Società Italiana dell’Ipertensione Arteriosa [in Italian]. G Ital Cardiol 1999 Mar; 29(3): 341–56PubMed Agabiti-Rosei E, Giovannini E, Mancia G, et al. Arterial hypertension and cardiac pathology: diagnostic and therapeutic guidelines presented by the Joint Commission of the ANMCO-SIC-SIIA. Associazione Nazionale Medici Cardiologi Ospedalieri. Società Italiana di Cardiologia. Società Italiana dell’Ipertensione Arteriosa [in Italian]. G Ital Cardiol 1999 Mar; 29(3): 341–56PubMed

go back to reference Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham Study. Ann Intern Med 1969 Jul; 71(1): 89–105PubMedCrossRef Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham Study. Ann Intern Med 1969 Jul; 71(1): 89–105PubMedCrossRef

go back to reference Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001 Oct 23; 104(17): 2039–44PubMedCrossRef Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001 Oct 23; 104(17): 2039–44PubMedCrossRef

go back to reference Savage DD, Drayer JI, Henry WL, et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation 1979 Apr; 59(4): 623–32PubMedCrossRef Savage DD, Drayer JI, Henry WL, et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation 1979 Apr; 59(4): 623–32PubMedCrossRef

go back to reference Cohen A, Hagan AD, Watkins J, et al. Clinical correlates in hypertensive patients with left ventricular hypertrophy diagnosed with echocardiography. Am J Cardiol 1981 Feb; 47(2): 335–41PubMedCrossRef Cohen A, Hagan AD, Watkins J, et al. Clinical correlates in hypertensive patients with left ventricular hypertrophy diagnosed with echocardiography. Am J Cardiol 1981 Feb; 47(2): 335–41PubMedCrossRef

go back to reference Carr AA, Prisant LM, Watkins LO. Detection of hypertensive left ventricular hypertrophy. Hypertension 1985 Nov-Dec; 7(6 Pt 1): 948–54PubMedCrossRef Carr AA, Prisant LM, Watkins LO. Detection of hypertensive left ventricular hypertrophy. Hypertension 1985 Nov-Dec; 7(6 Pt 1): 948–54PubMedCrossRef

go back to reference McLenachan JM, Henderson E, Morris KI, et al. Electrocardiographic diagnosis of left ventricular hypertrophy: influence of body build. Clin Sci 1988 Dec; 75(6): 589–92PubMedCrossRef McLenachan JM, Henderson E, Morris KI, et al. Electrocardiographic diagnosis of left ventricular hypertrophy: influence of body build. Clin Sci 1988 Dec; 75(6): 589–92PubMedCrossRef

go back to reference Rodríguez-Padial L, Navarro Lima A, Sánchez Domínguez J. RV6:RV5 voltage ratio in systemic hypertension. Am J Cardiol 1990 Oct 1; 66(10): 869–71PubMedCrossRef Rodríguez-Padial L, Navarro Lima A, Sánchez Domínguez J. RV6:RV5 voltage ratio in systemic hypertension. Am J Cardiol 1990 Oct 1; 66(10): 869–71PubMedCrossRef

go back to reference Otterstad E, Froeland G, Wasenius AK, et al. Validity of the ECG diagnosis of left ventricular hypertrophy in normotensive and moderately hypertensive men when using the echocardiographic assessment of left ventricular mass index as reference. J Hum Hypertens 1991 Apr; 5(2): 101–6PubMed Otterstad E, Froeland G, Wasenius AK, et al. Validity of the ECG diagnosis of left ventricular hypertrophy in normotensive and moderately hypertensive men when using the echocardiographic assessment of left ventricular mass index as reference. J Hum Hypertens 1991 Apr; 5(2): 101–6PubMed

go back to reference Vijan SG, Manning G, Millar-Craig MW. How reliable is the electrocardiogram in detecting left ventricular hypertrophy in hypertension? Postgrad Med J 1991 Jul; 67(789): 646–8PubMedPubMedCentralCrossRef Vijan SG, Manning G, Millar-Craig MW. How reliable is the electrocardiogram in detecting left ventricular hypertrophy in hypertension? Postgrad Med J 1991 Jul; 67(789): 646–8PubMedPubMedCentralCrossRef

go back to reference Lee DK, Marantz PR, Devereux RB, et al. Left ventricular hypertrophy in black and white hypertensives: standard electrocardiographic criteria overestimate racial differences in prevalence [published erratum appears in JAMA 1992 Dec 9; 268 (22): 3201]. JAMA 1992 Jun 24; 267(24): 3294–9PubMedCrossRef Lee DK, Marantz PR, Devereux RB, et al. Left ventricular hypertrophy in black and white hypertensives: standard electrocardiographic criteria overestimate racial differences in prevalence [published erratum appears in JAMA 1992 Dec 9; 268 (22): 3201]. JAMA 1992 Jun 24; 267(24): 3294–9PubMedCrossRef

go back to reference Fragola PV, Colivicchi F, Fabrizi E, et al. Assessment of left ventricular hypertrophy in patients with essential hypertension: a rational basis for the electrocardiogram. Am J Hypertens 1993 Feb; 6(2): 164–9PubMedCrossRef Fragola PV, Colivicchi F, Fabrizi E, et al. Assessment of left ventricular hypertrophy in patients with essential hypertension: a rational basis for the electrocardiogram. Am J Hypertens 1993 Feb; 6(2): 164–9PubMedCrossRef

go back to reference Schillaci G, Verdecchia P, Borgioni C, et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol 1994 Oct 1; 74(7): 714–9PubMedCrossRef Schillaci G, Verdecchia P, Borgioni C, et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol 1994 Oct 1; 74(7): 714–9PubMedCrossRef

go back to reference Casiglia E, Maniati G, Daskalakis C, et al. Left-ventricular hypertrophy in the elderly: unreliability of ECG criteria in 477 subjects aged 65 years or more. The CArdiovascular STudy in the ELderly (CASTEL). Cardiology 1996 Sep-Oct; 87(5): 429–35PubMedCrossRef Casiglia E, Maniati G, Daskalakis C, et al. Left-ventricular hypertrophy in the elderly: unreliability of ECG criteria in 477 subjects aged 65 years or more. The CArdiovascular STudy in the ELderly (CASTEL). Cardiology 1996 Sep-Oct; 87(5): 429–35PubMedCrossRef

go back to reference Verdecchia P, Angeli F, Reboldi G, et al. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens 2003 Aug; 16(8): 646–52PubMedCrossRef Verdecchia P, Angeli F, Reboldi G, et al. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens 2003 Aug; 16(8): 646–52PubMedCrossRef

go back to reference Levy D, Labib SB, Anderson KM, et al. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990 Mar; 81(3): 815–20PubMedCrossRef Levy D, Labib SB, Anderson KM, et al. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990 Mar; 81(3): 815–20PubMedCrossRef

go back to reference Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol 1998 Feb; 31(2): 383–90PubMedCrossRef Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol 1998 Feb; 31(2): 383–90PubMedCrossRef

go back to reference Okin PM, Roman MJ, Devereux RB, et al. Time-voltage QRS area of the 12-lead electrocardiogram: detection of left ventricular hypertrophy. Hypertension 1998 Apr; 31(4): 937–42PubMedCrossRef Okin PM, Roman MJ, Devereux RB, et al. Time-voltage QRS area of the 12-lead electrocardiogram: detection of left ventricular hypertrophy. Hypertension 1998 Apr; 31(4): 937–42PubMedCrossRef

go back to reference Okin PM, Jern S, Devereux RB, et al., for the LIFE Study Group. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 2000 Jan; 35(1 Pt 1): 13–8PubMedCrossRef Okin PM, Jern S, Devereux RB, et al., for the LIFE Study Group. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 2000 Jan; 35(1 Pt 1): 13–8PubMedCrossRef

go back to reference Romhilt DW, Estes EH. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J 1968 Jun; 75(6): 752–8PubMedCrossRef Romhilt DW, Estes EH. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J 1968 Jun; 75(6): 752–8PubMedCrossRef

go back to reference Okin PM, Devereux RB, Fabsitz RR, et al., for the Strong Heart Study. Quantitative assessment of electrocardiographic strain predicts increased left ventricular mass: the Strong Heart Study. J Am Coll Cardiol 2002 Oct 16; 40(8): 1395–400PubMedCrossRef Okin PM, Devereux RB, Fabsitz RR, et al., for the Strong Heart Study. Quantitative assessment of electrocardiographic strain predicts increased left ventricular mass: the Strong Heart Study. J Am Coll Cardiol 2002 Oct 16; 40(8): 1395–400PubMedCrossRef

go back to reference Okin PM, Devereux RB, Nieminen MS, et al., for the LIFE Study Investigators. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Circulation 2006 Jan 3; 113(1): 67–73PubMedCrossRef Okin PM, Devereux RB, Nieminen MS, et al., for the LIFE Study Investigators. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Circulation 2006 Jan 3; 113(1): 67–73PubMedCrossRef

go back to reference Okin PM, Devereux RB, Nieminen MS, et al., for the LIFE Study Investigators. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 2004 Jul; 44(1): 48–54PubMedCrossRef Okin PM, Devereux RB, Nieminen MS, et al., for the LIFE Study Investigators. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 2004 Jul; 44(1): 48–54PubMedCrossRef

go back to reference Schillaci G, Pirro M, Pasqualini L, et al. Prognostic significance of isolated, nonspecific left ventricular repolarization abnormalities in hypertension. J Hypertens 2004 Feb; 22(2): 407–14PubMedCrossRef Schillaci G, Pirro M, Pasqualini L, et al. Prognostic significance of isolated, nonspecific left ventricular repolarization abnormalities in hypertension. J Hypertens 2004 Feb; 22(2): 407–14PubMedCrossRef

go back to reference Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–87PubMedCrossRef Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–87PubMedCrossRef

go back to reference Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–71PubMedCrossRef Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–71PubMedCrossRef

go back to reference de Simone G. Guidelines for arterial hypertension: the echocardiography controversy. J Hypertens 1999 Jun; 17(6): 735–6PubMedCrossRef de Simone G. Guidelines for arterial hypertension: the echocardiography controversy. J Hypertens 1999 Jun; 17(6): 735–6PubMedCrossRef

go back to reference de Simone G, Schillaci G, Palmieri V, et al. Should all patients with hypertension have echocardiography? J Hum Hypertens 2000 Jul; 14(7): 417–21PubMedCrossRef de Simone G, Schillaci G, Palmieri V, et al. Should all patients with hypertension have echocardiography? J Hum Hypertens 2000 Jul; 14(7): 417–21PubMedCrossRef

go back to reference Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995 Oct; 13(10): 1091–5PubMedCrossRef Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995 Oct; 13(10): 1091–5PubMedCrossRef

go back to reference Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998 Jan 6-13; 97(1): 48–54PubMedCrossRef Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998 Jan 6-13; 97(1): 48–54PubMedCrossRef

go back to reference Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a metaanalysis. Am J Hypertens 2003 Nov; 16(11 Pt 1): 895–9PubMedCrossRef Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a metaanalysis. Am J Hypertens 2003 Nov; 16(11 Pt 1): 895–9PubMedCrossRef

go back to reference Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004 Nov 17; 292(19): 2350–6PubMedCrossRef Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004 Nov 17; 292(19): 2350–6PubMedCrossRef

go back to reference Levy D, Salomon M, D’Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994 Oct; 90(4): 1786–93PubMedCrossRef Levy D, Salomon M, D’Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994 Oct; 90(4): 1786–93PubMedCrossRef

go back to reference Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003 Aug 12; 108(6): 684–90PubMedCrossRef Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003 Aug 12; 108(6): 684–90PubMedCrossRef

go back to reference Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000 Feb; 35(2): 580–6PubMedCrossRef Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000 Feb; 35(2): 580–6PubMedCrossRef

go back to reference Lang RM, Bierig M, Devereux RB, et al. American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006 Mar; 7(2): 79–108PubMedCrossRef Lang RM, Bierig M, Devereux RB, et al. American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006 Mar; 7(2): 79–108PubMedCrossRef

go back to reference Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure and function by echocardiography and other non-invasive techniques. In: Laragh JH, Brenner BM, editors. Hypertension pathophysiology, diagnosis and management. New York: Raven Press, 1996: 1969–87 Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure and function by echocardiography and other non-invasive techniques. In: Laragh JH, Brenner BM, editors. Hypertension pathophysiology, diagnosis and management. New York: Raven Press, 1996: 1969–87

go back to reference de Simone G, Daniels SR, Kimball TR, et al. Evaluation of concentric left ventricular geometry in humans: evidence for age-related systematic underestimation. Hypertension 2005; 45(1): 64–8PubMedCrossRef de Simone G, Daniels SR, Kimball TR, et al. Evaluation of concentric left ventricular geometry in humans: evidence for age-related systematic underestimation. Hypertension 2005; 45(1): 64–8PubMedCrossRef

go back to reference Muiesan ML, Salvetti M, Monteduro C, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004 Apr; 43(4): 731–8PubMedCrossRef Muiesan ML, Salvetti M, Monteduro C, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004 Apr; 43(4): 731–8PubMedCrossRef

go back to reference de Simone G, Muiesan ML, Ganau A, et al. Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients: the RES trial. Working Group on Heart and Hypertension of the Italian Society of Hypertension: Reliability of M-mode Echocardiographic Studies. J Hypertens 1999 Dec; 17(12 Pt 2): 1955–63PubMedCrossRef de Simone G, Muiesan ML, Ganau A, et al. Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients: the RES trial. Working Group on Heart and Hypertension of the Italian Society of Hypertension: Reliability of M-mode Echocardiographic Studies. J Hypertens 1999 Dec; 17(12 Pt 2): 1955–63PubMedCrossRef

go back to reference Palmieri V, Dahlof B, DeQuattro V, et al. Reliability of echocardiography assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999 Nov 1; 34(5): 1625–32PubMedCrossRef Palmieri V, Dahlof B, DeQuattro V, et al. Reliability of echocardiography assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999 Nov 1; 34(5): 1625–32PubMedCrossRef

go back to reference Myerson SG, Montgomery HE, World MJ, et al. Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension 2002 Nov; 40(5): 673–8PubMedCrossRef Myerson SG, Montgomery HE, World MJ, et al. Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension 2002 Nov; 40(5): 673–8PubMedCrossRef

go back to reference Badano LP, Dall’ Armellina E, Bordin P, et al. Feasibility and clinical value of ‘intelligent’ compression and digital storage of transthoracic echocardiograms in day-to-day practice. Ital Heart J 2001 Oct; 2(10): 782–8PubMed Badano LP, Dall’ Armellina E, Bordin P, et al. Feasibility and clinical value of ‘intelligent’ compression and digital storage of transthoracic echocardiograms in day-to-day practice. Ital Heart J 2001 Oct; 2(10): 782–8PubMed

go back to reference Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990 May 31; 322(22): 1561–6PubMedCrossRef Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990 May 31; 322(22): 1561–6PubMedCrossRef

go back to reference de Simone G, Devereux RB, Koren MJ, et al. Midwall left ventricular mechanics: an independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996 Jan 15; 93(2): 259–65PubMedCrossRef de Simone G, Devereux RB, Koren MJ, et al. Midwall left ventricular mechanics: an independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996 Jan 15; 93(2): 259–65PubMedCrossRef

go back to reference de Simone G, Devereux RB. Rationale of echocardiographic assessment of left ventricular wall stress and midwall mechanics in hypertensive heart disease. Eur J Echocardiogr 2002 Sep; 3(3): 192–8PubMedCrossRef de Simone G, Devereux RB. Rationale of echocardiographic assessment of left ventricular wall stress and midwall mechanics in hypertensive heart disease. Eur J Echocardiogr 2002 Sep; 3(3): 192–8PubMedCrossRef

go back to reference Kizer JR, Bella JN, Palmieri V, et al. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middleaged and elderly adults: the Strong Heart Study (SHS). Am Heart J 2006 Feb; 151(2): 412–8PubMedCrossRef Kizer JR, Bella JN, Palmieri V, et al. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middleaged and elderly adults: the Strong Heart Study (SHS). Am Heart J 2006 Feb; 151(2): 412–8PubMedCrossRef

go back to reference Tsang TS, Abhayaratna WP, Barnes ME, et al. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol 2006 Mar 7; 47(5): 1018–23PubMedCrossRef Tsang TS, Abhayaratna WP, Barnes ME, et al. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol 2006 Mar 7; 47(5): 1018–23PubMedCrossRef

go back to reference Chinali M, de Simone G, Roman MJ, et al. Left atrial systolic force and cardiovascular outcome the strong heart study. Am J Hypertens 2005 Dec; 18 (12 Pt 1): 1570–6 Chinali M, de Simone G, Roman MJ, et al. Left atrial systolic force and cardiovascular outcome the strong heart study. Am J Hypertens 2005 Dec; 18 (12 Pt 1): 1570–6

go back to reference de Simone G, Kitzman DW, Chinali M, et al. Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. Eur Heart J 2005 May; 26(10): 1039–45PubMedCrossRef de Simone G, Kitzman DW, Chinali M, et al. Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. Eur Heart J 2005 May; 26(10): 1039–45PubMedCrossRef

go back to reference de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992 Nov 1; 20(5): 1251–60PubMedCrossRef de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992 Nov 1; 20(5): 1251–60PubMedCrossRef

go back to reference Dewey FE, Rosenthal D, Murphy Jr DJ, et al. Does size matter? Clinical applications of scaling cardiac size and function for body size. Circulation 2008; 117(17): 2279–87PubMedCrossRef Dewey FE, Rosenthal D, Murphy Jr DJ, et al. Does size matter? Clinical applications of scaling cardiac size and function for body size. Circulation 2008; 117(17): 2279–87PubMedCrossRef

go back to reference Abergel E, Chatellier G, Battaglia C, et al. Can echocardiography identify mildly hypertensive patients at high risk, left untreated based on current guidelines? J Hypertens 1999 Jun; 17(6): 817–24PubMedCrossRef Abergel E, Chatellier G, Battaglia C, et al. Can echocardiography identify mildly hypertensive patients at high risk, left untreated based on current guidelines? J Hypertens 1999 Jun; 17(6): 817–24PubMedCrossRef

go back to reference Schillaci G, de Simone G, Reboldi G, et al. Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens 2002 Aug; 20(8): 1519–25PubMedCrossRef Schillaci G, de Simone G, Reboldi G, et al. Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens 2002 Aug; 20(8): 1519–25PubMedCrossRef

go back to reference Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002 Jun 19; 39(12): 2005–11PubMedCrossRef Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002 Jun 19; 39(12): 2005–11PubMedCrossRef

go back to reference Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002 Apr 23; 105(16): 1928–33PubMedCrossRef Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002 Apr 23; 105(16): 1928–33PubMedCrossRef

go back to reference European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998 Jul; 19 (7): 990–1003 European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998 Jul; 19 (7): 990–1003

go back to reference Agabiti Rosei E, Muiesan ML. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. Blood Pressure 2001; 10(5-6): 288–98PubMedCrossRef Agabiti Rosei E, Muiesan ML. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. Blood Pressure 2001; 10(5-6): 288–98PubMedCrossRef

go back to reference Vakili B, Okin P, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001 Mar; 141(3): 334–41PubMedCrossRef Vakili B, Okin P, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001 Mar; 141(3): 334–41PubMedCrossRef

go back to reference Devereux RB, Agabiti-Rosei E, Dahlof B, et al. Regression of left ventricular hypertrophy is a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens Suppl 1996 Sep; 14(2): S95–101PubMedCrossRef Devereux RB, Agabiti-Rosei E, Dahlof B, et al. Regression of left ventricular hypertrophy is a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens Suppl 1996 Sep; 14(2): S95–101PubMedCrossRef

go back to reference Hinderliter A, Sherwood A, Gullette EC, et al. Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. Arch Intern Med 2002 Jun 24; 162 (12): 1333–9 Hinderliter A, Sherwood A, Gullette EC, et al. Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. Arch Intern Med 2002 Jun 24; 162 (12): 1333–9

go back to reference Ferrara LA, de Simone G, Pasanisi F, et al. Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension 1984 Sep-Oct; 6(5): 755–9PubMedCrossRef Ferrara LA, de Simone G, Pasanisi F, et al. Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension 1984 Sep-Oct; 6(5): 755–9PubMedCrossRef

go back to reference Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997 Mar 18; 95(6): 1464–70PubMedCrossRef Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997 Mar 18; 95(6): 1464–70PubMedCrossRef

go back to reference Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998 Mar; 13(3): 564–9PubMedCrossRef Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998 Mar; 13(3): 564–9PubMedCrossRef

go back to reference Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992 Feb; 5(2): 95–110PubMedCrossRef Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992 Feb; 5(2): 95–110PubMedCrossRef

go back to reference Cruickshank JM, Lewis J, Moore V, et al. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992 Apr; 6(2): 85–90PubMed Cruickshank JM, Lewis J, Moore V, et al. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992 Apr; 6(2): 85–90PubMed

go back to reference Fagard H. Reversibility of left ventricular hypertrophy by antihypertensive drugs. Neth J Med 1995 Oct; 47(4): 173–9PubMedCrossRef Fagard H. Reversibility of left ventricular hypertrophy by antihypertensive drugs. Neth J Med 1995 Oct; 47(4): 173–9PubMedCrossRef

go back to reference Jennings G, Wong J. Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. In: Hansonn L, Birkenhager WH, editors. Handbook of hypertension: assessment of hypertensive organ damage. Amsterdam: Elsevier Science BV, 1997: 185–223 Jennings G, Wong J. Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. In: Hansonn L, Birkenhager WH, editors. Handbook of hypertension: assessment of hypertensive organ damage. Amsterdam: Elsevier Science BV, 1997: 185–223

go back to reference Klingbeil AU, Scneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 Jul; 115(1): 41–6PubMedCrossRef Klingbeil AU, Scneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 Jul; 115(1): 41–6PubMedCrossRef

go back to reference Gottdiener J, Reda D, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension comparison of six antihypertensive agents: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive agents. Circulation 1997 Apr 15; 95(8): 2007–14PubMedCrossRef Gottdiener J, Reda D, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension comparison of six antihypertensive agents: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive agents. Circulation 1997 Apr 15; 95(8): 2007–14PubMedCrossRef

go back to reference Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995 Feb 1; 91(3): 698–706PubMedCrossRef Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995 Feb 1; 91(3): 698–706PubMedCrossRef

go back to reference Brilla CG, Funck RC, Rup H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000 Sep 19; 102(12): 1388–93PubMedCrossRef Brilla CG, Funck RC, Rup H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000 Sep 19; 102(12): 1388–93PubMedCrossRef

go back to reference Lopez B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001 Jul 17; 104(3): 286–91PubMedCrossRef Lopez B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001 Jul 17; 104(3): 286–91PubMedCrossRef

go back to reference Mathew J, Sleight P, Lonn E, et al., for the Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001 Oct 2; 104(14): 1615–21PubMedCrossRef Mathew J, Sleight P, Lonn E, et al., for the Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001 Oct 2; 104(14): 1615–21PubMedCrossRef

go back to reference Verdecchia P, Reboldi G, Angeli F, et al., for the HEART Survey Study Group. Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens 2007 Sep; 20(9): 997–1004PubMedCrossRef Verdecchia P, Reboldi G, Angeli F, et al., for the HEART Survey Study Group. Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens 2007 Sep; 20(9): 997–1004PubMedCrossRef

go back to reference Fagard RH, Staessen JA, Thijs L, et al. Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. Hypertension 2004 Oct; 44(4): 459–64PubMedCrossRef Fagard RH, Staessen JA, Thijs L, et al. Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. Hypertension 2004 Oct; 44(4): 459–64PubMedCrossRef

go back to reference Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006 Sep 13; 296(10): 1242–8PubMedCrossRef Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006 Sep 13; 296(10): 1242–8PubMedCrossRef

go back to reference Koren MJ, Ulin RJ, Koren AT, et al. Left ventricular mass changes during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002 Dec; 15(12): 1021–8PubMedCrossRef Koren MJ, Ulin RJ, Koren AT, et al. Left ventricular mass changes during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002 Dec; 15(12): 1021–8PubMedCrossRef

go back to reference Cipriano C, Gosse P, Bemurat L, et al. Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 2001 Jun; 14(6 Pt 1): 524–9PubMedCrossRef Cipriano C, Gosse P, Bemurat L, et al. Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 2001 Jun; 14(6 Pt 1): 524–9PubMedCrossRef

go back to reference Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint reduction in hypertension (LIFE) Study. Circulation 2004; 110(1 1): 1456–62PubMedCrossRef Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint reduction in hypertension (LIFE) Study. Circulation 2004; 110(1 1): 1456–62PubMedCrossRef

go back to reference Gerdts E, Cramariuc D, Watchell K, et al. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study) [abstract]. Eur Heart J 2006; 27Suppl.: 298 Gerdts E, Cramariuc D, Watchell K, et al. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study) [abstract]. Eur Heart J 2006; 27Suppl.: 298

go back to reference Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996 May 22–29; 275(20): 1557–62PubMedCrossRef Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996 May 22–29; 275(20): 1557–62PubMedCrossRef

go back to reference Lenfant C, Roccella EJ. A call to action for more aggressive treatment of hypertension. J Hypertens Suppl 1999 Feb; 17(1): S3–7PubMed Lenfant C, Roccella EJ. A call to action for more aggressive treatment of hypertension. J Hypertens Suppl 1999 Feb; 17(1): S3–7PubMed

go back to reference Haider AW, Larson MG, Franklin SS, et al., for the Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intem Med 2003 Jan 7; 138(1): 10–6CrossRef Haider AW, Larson MG, Franklin SS, et al., for the Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intem Med 2003 Jan 7; 138(1): 10–6CrossRef

go back to reference Tumbull F, for the Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intem Med 2005; 165: 1410–9CrossRef Tumbull F, for the Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intem Med 2005; 165: 1410–9CrossRef

go back to reference Volpe M, Rao MA, Tritto C, et al. Transition from asymptomatic left ventricular dysfunction to congestive heart failure. J Card Fail 1995 Dec; 1(5): 409–19PubMedCrossRef Volpe M, Rao MA, Tritto C, et al. Transition from asymptomatic left ventricular dysfunction to congestive heart failure. J Card Fail 1995 Dec; 1(5): 409–19PubMedCrossRef

go back to reference Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003 Aug 26; 108(8): 977–82PubMedCrossRef Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003 Aug 26; 108(8): 977–82PubMedCrossRef

go back to reference Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000 Jun; 5(2): 167–73PubMedCrossRef Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000 Jun; 5(2): 167–73PubMedCrossRef

go back to reference Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology of ‘asymptomatic’ left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003 Jun 3; 138(11): 907–16PubMedCrossRef Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology of ‘asymptomatic’ left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003 Jun 3; 138(11): 907–16PubMedCrossRef

go back to reference Verdecchia P, Angeli F, Gattobigio R, et al. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension 2005 Mar; 45(3): 412–8PubMedCrossRef Verdecchia P, Angeli F, Gattobigio R, et al. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension 2005 Mar; 45(3): 412–8PubMedCrossRef

go back to reference Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999 Jun; 33(7): 1948–55PubMedCrossRef Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999 Jun; 33(7): 1948–55PubMedCrossRef

go back to reference Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000 May 2; 101(17): 2118–2PubMedCrossRef Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000 May 2; 101(17): 2118–2PubMedCrossRef

go back to reference Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006 Jul 20; 355(3): 251–9PubMedCrossRef Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006 Jul 20; 355(3): 251–9PubMedCrossRef

go back to reference Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007 Oct; 28(20): 2539–50PubMedCrossRef Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007 Oct; 28(20): 2539–50PubMedCrossRef

go back to reference Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006 Jul 20; 355(3): 260–9PubMedCrossRef Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006 Jul 20; 355(3): 260–9PubMedCrossRef

go back to reference Emdin M, Clerico A, Clemenza F, et al. Recommendations for the clinical use of cardiac natriuretic peptides [in Italian]. Ital Heart J 2005 May; 6(5): 308–25 Emdin M, Clerico A, Clemenza F, et al. Recommendations for the clinical use of cardiac natriuretic peptides [in Italian]. Ital Heart J 2005 May; 6(5): 308–25

go back to reference Galderisi M, Dini FL, Temporelli PL, et al. Doppler echocardiography for the assessment of left ventricular diastolic function: methodology, clinical and prognostic value [in Italian]. Ital Heart J Suppl 2004 Feb; 5(2): 86–97PubMed Galderisi M, Dini FL, Temporelli PL, et al. Doppler echocardiography for the assessment of left ventricular diastolic function: methodology, clinical and prognostic value [in Italian]. Ital Heart J Suppl 2004 Feb; 5(2): 86–97PubMed

go back to reference Redfield MM, Jacobsen SJ, Bumett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community. JAMA 2003 Jan 8; 289(2): 194–202PubMedCrossRef Redfield MM, Jacobsen SJ, Bumett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community. JAMA 2003 Jan 8; 289(2): 194–202PubMedCrossRef

go back to reference Rakowski H, Appleton C, Chan KL, et al. Canadian consensus reccommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of the Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 1996 Sep–Oct; 9(5): 736–60PubMedCrossRef Rakowski H, Appleton C, Chan KL, et al. Canadian consensus reccommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of the Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 1996 Sep–Oct; 9(5): 736–60PubMedCrossRef

go back to reference Zanchetti A, Cuspidi C, Comarell L, et al. Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study. J Hypertens 2007; 25(10): 2158–67PubMedCrossRef Zanchetti A, Cuspidi C, Comarell L, et al. Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study. J Hypertens 2007; 25(10): 2158–67PubMedCrossRef

go back to reference Almuntaser I, Brown A, Murphy R, et al. Comparison of echocardiographic measures of left ventricular diastolic function in early hypertension. Am J Cardiol 2007 Dec 15; 100(12): 1771–5PubMedCrossRef Almuntaser I, Brown A, Murphy R, et al. Comparison of echocardiographic measures of left ventricular diastolic function in early hypertension. Am J Cardiol 2007 Dec 15; 100(12): 1771–5PubMedCrossRef

go back to reference Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure. J Am Coll Cardiol 2001 Mar 15; 37(4): 1042–8PubMedCrossRef Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure. J Am Coll Cardiol 2001 Mar 15; 37(4): 1042–8PubMedCrossRef

go back to reference Poole-Wilson PA, Lubsen J, Kirwan BA, et al. A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system (ACTION) Investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment trial: randomised controlled trial. Lancet 2004; 364(9437): 849–57PubMedCrossRef Poole-Wilson PA, Lubsen J, Kirwan BA, et al. A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system (ACTION) Investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment trial: randomised controlled trial. Lancet 2004; 364(9437): 849–57PubMedCrossRef

go back to reference Dahlof B, Devereux RB, Kjeldsen SE, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet 2002; 359: 995–1003PubMedCrossRef Dahlof B, Devereux RB, Kjeldsen SE, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet 2002; 359: 995–1003PubMedCrossRef

go back to reference Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) randomised trial. Lancet 2004; 363(9426): 2022–31PubMedCrossRef Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) randomised trial. Lancet 2004; 363(9426): 2022–31PubMedCrossRef

go back to reference Volpe M, Ruilope LM, McInnes GT, et al. Angiotensin-I1 receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005, 19;331–9PubMedCrossRef Volpe M, Ruilope LM, McInnes GT, et al. Angiotensin-I1 receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005, 19;331–9PubMedCrossRef

go back to reference Hunt SA, for the American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005 Sep 20; 46(6): el–82CrossRef Hunt SA, for the American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005 Sep 20; 46(6): el–82CrossRef

go back to reference Swedberg K, Cleland J, Dargie H, et al., for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005 Jun; 26(11): 1115–40PubMedCrossRef Swedberg K, Cleland J, Dargie H, et al., for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005 Jun; 26(11): 1115–40PubMedCrossRef

go back to reference The Cooperative North Scandinavian ENalapril Survival (CONSENSUS) Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429–35 The Cooperative North Scandinavian ENalapril Survival (CONSENSUS) Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429–35

go back to reference The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. Studies Of Left Ventricular Dysfunction (SOLVD). N Engl J Med 1991; 325: 293–302 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. Studies Of Left Ventricular Dysfunction (SOLVD). N Engl J Med 1991; 325: 293–302

go back to reference Vantrimpont P, Rouleau L, Wun CC, et al. for the SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival And Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol 1997; 29(2): 229–36CrossRef Vantrimpont P, Rouleau L, Wun CC, et al. for the SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival And Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol 1997; 29(2): 229–36CrossRef

go back to reference Pitt B, Segal R, Martinez FA, et al., on behalf of The Evaluation of Losartan In The Elderly (ELlTE) Study. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997; 349(9054): 747–52PubMedCrossRef Pitt B, Segal R, Martinez FA, et al., on behalf of The Evaluation of Losartan In The Elderly (ELlTE) Study. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997; 349(9054): 747–52PubMedCrossRef

go back to reference Cohn JN, Tagnoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the Angiotensin I1 Receptor Blocker Valsartan in Congestive Heart Failure (Val-HeFT). N Engl J Med 2001; 345: 1667–75PubMedCrossRef Cohn JN, Tagnoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the Angiotensin I1 Receptor Blocker Valsartan in Congestive Heart Failure (Val-HeFT). N Engl J Med 2001; 345: 1667–75PubMedCrossRef

go back to reference Pfeffer MA, Swedber K, Granger CB, et al., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the Candesartan cilexitil in Heart failure: Assessment of Reduction in morbidity and Mortality (CHARM) Overall Programme. Lancet 2003; 362: 759–66PubMedCrossRef Pfeffer MA, Swedber K, Granger CB, et al., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the Candesartan cilexitil in Heart failure: Assessment of Reduction in morbidity and Mortality (CHARM) Overall Programme. Lancet 2003; 362: 759–66PubMedCrossRef

go back to reference The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342 (8875): 821–8 The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342 (8875): 821–8

go back to reference Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. TRAndolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333(25): 1670–6PubMedCrossRef Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. TRAndolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333(25): 1670–6PubMedCrossRef

go back to reference Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the Optimal Trial In Myocardial infarction with the Angiotensin I1 Antagonist Losartan (OPTIMAAL). Lancet 2002; 360: 60–75 Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the Optimal Trial In Myocardial infarction with the Angiotensin I1 Antagonist Losartan (OPTIMAAL). Lancet 2002; 360: 60–75

go back to reference Carson P, Massie BM, McKelvie R, et al., for the I-PRESERVE Investigators. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005; 11(8): 576–85PubMedCrossRef Carson P, Massie BM, McKelvie R, et al., for the I-PRESERVE Investigators. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005; 11(8): 576–85PubMedCrossRef

go back to reference Strauer BE, Motz W, Schwartzkopff B, et al. The heart in hypertension. In: Swales JD, editor. Textbook of hypertension. Boston (MA): Blackwell Scientific Publications, 1994: 712–31 Strauer BE, Motz W, Schwartzkopff B, et al. The heart in hypertension. In: Swales JD, editor. Textbook of hypertension. Boston (MA): Blackwell Scientific Publications, 1994: 712–31

go back to reference Lang CC, Lip GYH. Complication of hypertension: the heart. In: Crawford MH, DiMarco JP, Paulus WP, editors. Cardiology. Philadelphia (PA): Mosby Elsevier Ltd, 2004: 489–500 Lang CC, Lip GYH. Complication of hypertension: the heart. In: Crawford MH, DiMarco JP, Paulus WP, editors. Cardiology. Philadelphia (PA): Mosby Elsevier Ltd, 2004: 489–500

go back to reference Tomanek RJ. Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 1990 Mar 1; 15(3): 528–33PubMedCrossRef Tomanek RJ. Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 1990 Mar 1; 15(3): 528–33PubMedCrossRef

go back to reference Egashira K, Suzuki S, Hirooka Y, et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension: different responses to acetylcholine and substance P. Hypertension. 1995 Feb; 25(2): 201–6PubMedCrossRef Egashira K, Suzuki S, Hirooka Y, et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension: different responses to acetylcholine and substance P. Hypertension. 1995 Feb; 25(2): 201–6PubMedCrossRef

go back to reference Wever RM, Luscher TF, Cosentino F, et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998 Jan 6–13; 97(1): 108–12PubMedCrossRef Wever RM, Luscher TF, Cosentino F, et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998 Jan 6–13; 97(1): 108–12PubMedCrossRef

go back to reference Zeiher AM, Fisslthale B, Schray-Utz B, et al. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995 Jun; 76(6): 980–6PubMedCrossRef Zeiher AM, Fisslthale B, Schray-Utz B, et al. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995 Jun; 76(6): 980–6PubMedCrossRef

go back to reference Libby P. Changing concepts of atherogenesis. J Intern Med 2000 Mar; 247(3): 349–58PubMedCrossRef Libby P. Changing concepts of atherogenesis. J Intern Med 2000 Mar; 247(3): 349–58PubMedCrossRef

go back to reference Antoni I, Nitenberg A. Coronary artery reserve is similarly reduced in hypertensive patients without any other coronary risk factors and in normotensive smokers and hypercholesterolemic patients with angiographically normal coronary arteries. Am J Hypertens 1997 Feb; 10(2): 181–8CrossRef Antoni I, Nitenberg A. Coronary artery reserve is similarly reduced in hypertensive patients without any other coronary risk factors and in normotensive smokers and hypercholesterolemic patients with angiographically normal coronary arteries. Am J Hypertens 1997 Feb; 10(2): 181–8CrossRef

go back to reference Scheler S, Motz W, Strauer BE. Mechanisms of angina pectoris in patients with systemic hypertension and normal epicardial coronary arteries by arteriogram. Am J Cardiol 1994 Mar 1; 73(7): 478–82PubMedCrossRef Scheler S, Motz W, Strauer BE. Mechanisms of angina pectoris in patients with systemic hypertension and normal epicardial coronary arteries by arteriogram. Am J Cardiol 1994 Mar 1; 73(7): 478–82PubMedCrossRef

go back to reference Kozakova M, Fraser AG, Buralli S, et al. Reduced left ventricular functional reserve in hypertensive patients with preserved function at rest. Hypertension 2005 Apr; 45(4): 619–24PubMedCrossRef Kozakova M, Fraser AG, Buralli S, et al. Reduced left ventricular functional reserve in hypertensive patients with preserved function at rest. Hypertension 2005 Apr; 45(4): 619–24PubMedCrossRef

go back to reference Uren NG, Crake T, Lefroy DC, et al. Reduced coronary vasodilator function in infracted and normal myocardium after myocardial infarction. N Engl J Med 1994 Jul 28; 331(4): 222–7PubMedCrossRef Uren NG, Crake T, Lefroy DC, et al. Reduced coronary vasodilator function in infracted and normal myocardium after myocardial infarction. N Engl J Med 1994 Jul 28; 331(4): 222–7PubMedCrossRef

go back to reference Uren NG, Marracini P, Gistri R, et al. Altered coronary vasodilator reserve and metabolism in myocardium subtended by normal arteries in patients with coronary artery disease. J Am Coll Cardiol 1993 Sep; 22(3): 650–8PubMedCrossRef Uren NG, Marracini P, Gistri R, et al. Altered coronary vasodilator reserve and metabolism in myocardium subtended by normal arteries in patients with coronary artery disease. J Am Coll Cardiol 1993 Sep; 22(3): 650–8PubMedCrossRef

go back to reference Picano E, Palinkas A, Amyot R. Diagnosis of myocardial ischemia in hypertensive patients. J Hypertens 2001 Jul; 19(7): 1177–83PubMedCrossRef Picano E, Palinkas A, Amyot R. Diagnosis of myocardial ischemia in hypertensive patients. J Hypertens 2001 Jul; 19(7): 1177–83PubMedCrossRef

go back to reference Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease: a meta-analysis. Circulation 1989 Jul; 80(1): 87–98PubMedCrossRef Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease: a meta-analysis. Circulation 1989 Jul; 80(1): 87–98PubMedCrossRef

go back to reference Froelicher VF, Lehman KG, Thomas R. The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction.Veterans Affairs Cooperative Study in Health Services #016 (QUEXTA) Study Group. Quantitative Exercise Testing and Angiography. Ann Intern Med 1998 Jun 15; 128(12 Pt 1): 965–74PubMedCrossRef Froelicher VF, Lehman KG, Thomas R. The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction.Veterans Affairs Cooperative Study in Health Services #016 (QUEXTA) Study Group. Quantitative Exercise Testing and Angiography. Ann Intern Med 1998 Jun 15; 128(12 Pt 1): 965–74PubMedCrossRef

go back to reference Chaitman BR. Exercise stress testing. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. Philadelphia (PA): Elsevier Saunders, 2005: 172–3 Chaitman BR. Exercise stress testing. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. Philadelphia (PA): Elsevier Saunders, 2005: 172–3

go back to reference Picano E. Microvasculopatia coronarica: sindrome X, cardiomiopatia ipertrofica, ipertensione arteriosa. In: Picano E, editor, Stress echocardiography. Ecocardiografia da stress. Milan: Springer Verlag, 2004: 355 Picano E. Microvasculopatia coronarica: sindrome X, cardiomiopatia ipertrofica, ipertensione arteriosa. In: Picano E, editor, Stress echocardiography. Ecocardiografia da stress. Milan: Springer Verlag, 2004: 355

go back to reference Gibbsons RJ, Balady GJ, Bricker IT, et al., for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines) ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002 Oct 1; 106(14): 1883–92CrossRef Gibbsons RJ, Balady GJ, Bricker IT, et al., for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines) ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002 Oct 1; 106(14): 1883–92CrossRef

go back to reference Novo S, Barbagallo M, Abrignani MG, et al. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary artery disease. Am J Hypertens 1997 Aug; 10(8): 843–51PubMedCrossRef Novo S, Barbagallo M, Abrignani MG, et al. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary artery disease. Am J Hypertens 1997 Aug; 10(8): 843–51PubMedCrossRef

go back to reference Crawford MH, Bernstein J, Deedwania C, et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the guidelines for ambulatory electrocardiography). Circulation 1999 Aug 24; 100(8): 886–93PubMedCrossRef Crawford MH, Bernstein J, Deedwania C, et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the guidelines for ambulatory electrocardiography). Circulation 1999 Aug 24; 100(8): 886–93PubMedCrossRef

go back to reference Fragasso G, Lu C, Dabrowski P, et al. Comparison of stresslrest myocardial perfusion tomography, and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. J Am Coll Cardiol 1999 Aug; 34(2): 441–7PubMedCrossRef Fragasso G, Lu C, Dabrowski P, et al. Comparison of stresslrest myocardial perfusion tomography, and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. J Am Coll Cardiol 1999 Aug; 34(2): 441–7PubMedCrossRef

go back to reference Astarita C, Palinkas A, Nicolai E, et al. Dypiridamole-atropine stress echocardiography versus exercise SPECT scintigraphy for detection of coronary artery disease in hypertensives with positive exercise test. J Hypertens 2001 Mar; 193): 495–502PubMedCrossRef Astarita C, Palinkas A, Nicolai E, et al. Dypiridamole-atropine stress echocardiography versus exercise SPECT scintigraphy for detection of coronary artery disease in hypertensives with positive exercise test. J Hypertens 2001 Mar; 193): 495–502PubMedCrossRef

go back to reference Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography. A Report of the American College of Cardiology/American Heart Sssociation Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003 Sep 2; 108(9): 1146–62PubMedCrossRef Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography. A Report of the American College of Cardiology/American Heart Sssociation Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003 Sep 2; 108(9): 1146–62PubMedCrossRef

go back to reference Cortigiani L, Zanetti L, Bigi R, et al. Safety and feasibility of dobutamine and dypiridamole stress echocardiographyin hypertensive patients. J Hypertens 2002 Jul; 20(7): 1423–9PubMedCrossRef Cortigiani L, Zanetti L, Bigi R, et al. Safety and feasibility of dobutamine and dypiridamole stress echocardiographyin hypertensive patients. J Hypertens 2002 Jul; 20(7): 1423–9PubMedCrossRef

go back to reference Strauer BE, Schwarzkopff B, Kelm M. Assessing the coronary circulation in hypertension. J Hypertens 1998 Sep; 16(9): 1221–33PubMedCrossRef Strauer BE, Schwarzkopff B, Kelm M. Assessing the coronary circulation in hypertension. J Hypertens 1998 Sep; 16(9): 1221–33PubMedCrossRef

go back to reference Marwick TH, Case C, Sawad S, et al. Prediction of outcomes in hypertensive patients with suspected coronary disease. Hypertension 2002 Jun; 39(6): 1113–8PubMedCrossRef Marwick TH, Case C, Sawad S, et al. Prediction of outcomes in hypertensive patients with suspected coronary disease. Hypertension 2002 Jun; 39(6): 1113–8PubMedCrossRef

go back to reference Lucarini AR, Picano E, Lattanzi F, et al. Dypyridamole echocardiography stresstesting in hypertensive patients: targets and tools. Circulation 1991 May; 83(5 Suppl.): 11168–72 Lucarini AR, Picano E, Lattanzi F, et al. Dypyridamole echocardiography stresstesting in hypertensive patients: targets and tools. Circulation 1991 May; 83(5 Suppl.): 11168–72

go back to reference Picano E, Bedetti G, Varga A, et al. The comparable diagnostic accuracy of dobutamine and dypyridamole stress echocardiography: a meta-analysis. Coronary Artery Dis 2000 Mar; 11(2): 151–9CrossRef Picano E, Bedetti G, Varga A, et al. The comparable diagnostic accuracy of dobutamine and dypyridamole stress echocardiography: a meta-analysis. Coronary Artery Dis 2000 Mar; 11(2): 151–9CrossRef

go back to reference Cortigiani L, Paolini EA, Nannini E. Dypiridamole stress test echocardiography for risk stratification in hypertensive patients with chest pain. Circulation 1998 Dec 22–29; 98(25): 2855–9PubMedCrossRef Cortigiani L, Paolini EA, Nannini E. Dypiridamole stress test echocardiography for risk stratification in hypertensive patients with chest pain. Circulation 1998 Dec 22–29; 98(25): 2855–9PubMedCrossRef

go back to reference Mondillo S, Agricola E, Ammaturo T, et al. Prognostic value of dypiridamole stress echocardiography in hypertensive patients with left ventricular hypertrophy, chest pain and resting electrocardiographic abnormalities. Can J Cardiol 2001 May; 17(5): 571–7PubMed Mondillo S, Agricola E, Ammaturo T, et al. Prognostic value of dypiridamole stress echocardiography in hypertensive patients with left ventricular hypertrophy, chest pain and resting electrocardiographic abnormalities. Can J Cardiol 2001 May; 17(5): 571–7PubMed

go back to reference Picano E, Lucarini AR, Lattanzi F, et al. Dipyridamole echocardiography in essential hypertensive patients with chest pain. Hypertension 1988 Sep; 12(3): 238–43PubMedCrossRef Picano E, Lucarini AR, Lattanzi F, et al. Dipyridamole echocardiography in essential hypertensive patients with chest pain. Hypertension 1988 Sep; 12(3): 238–43PubMedCrossRef

go back to reference Imran MB, Palinkka A, Pican E. Head-to-head comparison dypiridamole echocardiography and stress perfusion scintigraphy for the detection of coronary artery disease: a meta-analysis. Int J Cardiovasc Imaging 2003 Feb; 19(1): 23–8PubMedCrossRef Imran MB, Palinkka A, Pican E. Head-to-head comparison dypiridamole echocardiography and stress perfusion scintigraphy for the detection of coronary artery disease: a meta-analysis. Int J Cardiovasc Imaging 2003 Feb; 19(1): 23–8PubMedCrossRef

go back to reference Cortigiani L, Bigi R, Rigo F, et al., on behalf of the Echo Persantine International Cooperative (EPIC) Study Group. Diagnostic value of exercise electrocardiography and dipyridamole stress echocardiography in hypertensive and normotensive chest pain patients with right bundle branch block. J Hypertens 2003 Nov; 21(11): 2189–94PubMedCrossRef Cortigiani L, Bigi R, Rigo F, et al., on behalf of the Echo Persantine International Cooperative (EPIC) Study Group. Diagnostic value of exercise electrocardiography and dipyridamole stress echocardiography in hypertensive and normotensive chest pain patients with right bundle branch block. J Hypertens 2003 Nov; 21(11): 2189–94PubMedCrossRef

go back to reference Del Porto R, Faletra F, Picano E, et al. Safety feasibility and diagnostic accuracy of accelerated high dose dypiridamole stress echocardiography. Am J Cardiol 2001 Mar 1; 87(5): 520–4CrossRef Del Porto R, Faletra F, Picano E, et al. Safety feasibility and diagnostic accuracy of accelerated high dose dypiridamole stress echocardiography. Am J Cardiol 2001 Mar 1; 87(5): 520–4CrossRef

go back to reference Senior R, Basu S, Handler C, et al. Diagnostic accuracy of dobutamine stress echocardiography for detection of coronary artery disease in hypertensive patients. Eur Heart J 1996 Feb; 17(2): 289–95PubMedCrossRef Senior R, Basu S, Handler C, et al. Diagnostic accuracy of dobutamine stress echocardiography for detection of coronary artery disease in hypertensive patients. Eur Heart J 1996 Feb; 17(2): 289–95PubMedCrossRef

go back to reference Kawano H, Fujii H, Kugiyama K, et al. Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography. Am J Cardiol 2000 Jan 1; 85(1): 26–30PubMedCrossRef Kawano H, Fujii H, Kugiyama K, et al. Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography. Am J Cardiol 2000 Jan 1; 85(1): 26–30PubMedCrossRef

go back to reference Bigi R, Bax JJ, van Domburg RT, et al. Simultaneous echocardiography and myocardial perfusion single photon emission computed tomography associated with dobutamine stress to predict long-term cardiac mortality in normotensive and hypertensive patients. J Hypertens 2005 Jul; 23(7): 1409–15PubMedCrossRef Bigi R, Bax JJ, van Domburg RT, et al. Simultaneous echocardiography and myocardial perfusion single photon emission computed tomography associated with dobutamine stress to predict long-term cardiac mortality in normotensive and hypertensive patients. J Hypertens 2005 Jul; 23(7): 1409–15PubMedCrossRef

go back to reference Armstrong WF, O’Donnell J, Ryan T, et al. Effect of prior myocardial infarction and extent and location of coronary artery disease on accuracy of exercise echocardiography. J Am Coll Cardiol 1987 Sep; 10(3): 531–8PubMedCrossRef Armstrong WF, O’Donnell J, Ryan T, et al. Effect of prior myocardial infarction and extent and location of coronary artery disease on accuracy of exercise echocardiography. J Am Coll Cardiol 1987 Sep; 10(3): 531–8PubMedCrossRef

go back to reference Badruddin SM, Badruddin SM, Ahmad A, Mickelson J, et al. Supine bycicle versus posttreadmill exercise echocardiography in the detection of myocardial ischemia: arandomized single-blind crossover trial. J Am Coll Cardiol 1999 May; 33(6): 1485–90PubMedCrossRef Badruddin SM, Badruddin SM, Ahmad A, Mickelson J, et al. Supine bycicle versus posttreadmill exercise echocardiography in the detection of myocardial ischemia: arandomized single-blind crossover trial. J Am Coll Cardiol 1999 May; 33(6): 1485–90PubMedCrossRef

go back to reference Quiiioñes MA, Verani MS, Haichim RM, et al. Exercise echocardiography versus thallium-201 single-photon computed emission tomography in evaluation of coronary artery disease: analysis of 292 patients. Circulation 1992 Mar; 85(3): 1026–31CrossRef Quiiioñes MA, Verani MS, Haichim RM, et al. Exercise echocardiography versus thallium-201 single-photon computed emission tomography in evaluation of coronary artery disease: analysis of 292 patients. Circulation 1992 Mar; 85(3): 1026–31CrossRef

go back to reference Mason SJ, Weiss JL, Weisfeldt ML, et al. Exercise echocardiography in detection of wall motion abnormalities during ischemia. Circulation 1979 Jan; 59(1): 50–9PubMedCrossRef Mason SJ, Weiss JL, Weisfeldt ML, et al. Exercise echocardiography in detection of wall motion abnormalities during ischemia. Circulation 1979 Jan; 59(1): 50–9PubMedCrossRef

go back to reference Crouse J, Harbrecht JJ, Vacek JL, et al. Exercise echocardiography as a screening test for coronary artery disease and correlation with coronary angiography. Am J Cardiol 1991 Jun 1; 67(15): 1213–8PubMedCrossRef Crouse J, Harbrecht JJ, Vacek JL, et al. Exercise echocardiography as a screening test for coronary artery disease and correlation with coronary angiography. Am J Cardiol 1991 Jun 1; 67(15): 1213–8PubMedCrossRef

go back to reference Galanti G, Sciagrà R, Comeglio M, et al. Diagnostic accuracy of peak exercise echocardiography in coronary artery disease: comparison with thallium-201 scintigraphy. Am Heart J 1991 Dec; 122(6): 1609–16PubMedCrossRef Galanti G, Sciagrà R, Comeglio M, et al. Diagnostic accuracy of peak exercise echocardiography in coronary artery disease: comparison with thallium-201 scintigraphy. Am Heart J 1991 Dec; 122(6): 1609–16PubMedCrossRef

go back to reference Maltagliati A, Bert M, Muratori M. Exercise echocardiography versus exercise electrocardiography in the diagnosis of coronary artery disease in hypertension. Am J Hypertens 2000 Jul; 13(7): 796–801PubMedCrossRef Maltagliati A, Bert M, Muratori M. Exercise echocardiography versus exercise electrocardiography in the diagnosis of coronary artery disease in hypertension. Am J Hypertens 2000 Jul; 13(7): 796–801PubMedCrossRef

go back to reference Pasierski T, Szwed H, Malczewska B, et al. Advantages of exercise echocardiography in comparison with dobutamine echocardiography in the diagnosis of coronary artery disease in hypertensive subjects. J Hum Hypertens 2001 Nov; 15(11): 805–9PubMedCrossRef Pasierski T, Szwed H, Malczewska B, et al. Advantages of exercise echocardiography in comparison with dobutamine echocardiography in the diagnosis of coronary artery disease in hypertensive subjects. J Hum Hypertens 2001 Nov; 15(11): 805–9PubMedCrossRef

go back to reference Gould KL, Lipscomb K. Effects of coronary stenosis on coronary flow reserve and resistance. Am J Cardiol 1974 Jul; 34(1): 48–55PubMedCrossRef Gould KL, Lipscomb K. Effects of coronary stenosis on coronary flow reserve and resistance. Am J Cardiol 1974 Jul; 34(1): 48–55PubMedCrossRef

go back to reference Alberta M, Voskuil M, Piek J, et al. for the Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) I1 Study Group. Coronary flow velocity reserve after percutaneous interventions is predictive of periprocedural outcome. Circulation 2002 Apr 2; 105(13): 1573–8CrossRef Alberta M, Voskuil M, Piek J, et al. for the Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) I1 Study Group. Coronary flow velocity reserve after percutaneous interventions is predictive of periprocedural outcome. Circulation 2002 Apr 2; 105(13): 1573–8CrossRef

go back to reference Rigo F, Varga Z, Di Pede F, et al. Early assessment of coronary flow reserve by transthoracic Doppler echocardiography predicts late remodeling in reperfused anterior myocardial infarction. J Am Soc Echocardiogr 2004 Jul; 17(7): 750–5PubMedCrossRef Rigo F, Varga Z, Di Pede F, et al. Early assessment of coronary flow reserve by transthoracic Doppler echocardiography predicts late remodeling in reperfused anterior myocardial infarction. J Am Soc Echocardiogr 2004 Jul; 17(7): 750–5PubMedCrossRef

go back to reference Bolognese L, Carabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004 Mar 9; 109(9): 1121–6PubMedCrossRef Bolognese L, Carabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004 Mar 9; 109(9): 1121–6PubMedCrossRef

go back to reference Rigo F, Gherardi S, Galderisi M, et al. Coronary flow reserve in stress-echocardiography laboratory. J Cardiovasc Med 2006 Jul; 7(7): 472–9CrossRef Rigo F, Gherardi S, Galderisi M, et al. Coronary flow reserve in stress-echocardiography laboratory. J Cardiovasc Med 2006 Jul; 7(7): 472–9CrossRef

go back to reference Hozumi T, Yoshida K, Ogata Y, et al. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998 Apr 28; 97(16): 1557–62PubMedCrossRef Hozumi T, Yoshida K, Ogata Y, et al. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998 Apr 28; 97(16): 1557–62PubMedCrossRef

go back to reference Chin WL, O’Kelly B, Tubau JF, et al. Diagnostic accuracy of exercise thallium-201 scintigraphy in men with asymptomatic essential hypertension. Am J Hypertens 1992 Jul; 5(7): 465–72PubMedCrossRef Chin WL, O’Kelly B, Tubau JF, et al. Diagnostic accuracy of exercise thallium-201 scintigraphy in men with asymptomatic essential hypertension. Am J Hypertens 1992 Jul; 5(7): 465–72PubMedCrossRef

go back to reference Prisant LM, Von Dohlen TW, Houghton JL, et al. A negative thallium (± dipyridamole) stress test excludes significant obstructive epicardial coronary disease in hypertensive patients. Am J Hypertens 1992 Feb; 5(2): 71–5PubMedCrossRef Prisant LM, Von Dohlen TW, Houghton JL, et al. A negative thallium (± dipyridamole) stress test excludes significant obstructive epicardial coronary disease in hypertensive patients. Am J Hypertens 1992 Feb; 5(2): 71–5PubMedCrossRef

go back to reference Houghton TL, Frank MJ, Carr AA, et al. Relations among imapired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990 Jan; 15(1): 43–51PubMedCrossRef Houghton TL, Frank MJ, Carr AA, et al. Relations among imapired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990 Jan; 15(1): 43–51PubMedCrossRef

go back to reference Fleischmann KE, Hunink MG, Kunz KM, et al. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998 Sep 9; 280(10): 913–20PubMedCrossRef Fleischmann KE, Hunink MG, Kunz KM, et al. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998 Sep 9; 280(10): 913–20PubMedCrossRef

go back to reference Kymes SM, Bruns DE, Shaw LJ, et al. Anatomy of a meta-analysis: a critical review of ‘exercise echocardiography or exercise SPECT imaging? A metaanalysis of diagnostic test performance’. J Nucl Cardiol 2000 Nov–Dec; 7(6): 599–615PubMedCrossRef Kymes SM, Bruns DE, Shaw LJ, et al. Anatomy of a meta-analysis: a critical review of ‘exercise echocardiography or exercise SPECT imaging? A metaanalysis of diagnostic test performance’. J Nucl Cardiol 2000 Nov–Dec; 7(6): 599–615PubMedCrossRef

go back to reference De Albuquerque Fonseca L, Picano E. Comparison of dypiridamole and exercise stress echocardiography for detection of coronary artery disease (a meta-analysis). Am J Cardiol 2001 May 15; 87(10): 1193–6PubMedCrossRef De Albuquerque Fonseca L, Picano E. Comparison of dypiridamole and exercise stress echocardiography for detection of coronary artery disease (a meta-analysis). Am J Cardiol 2001 May 15; 87(10): 1193–6PubMedCrossRef

go back to reference Berrington De Gonzales A, Darby S. Risk of cancer form diagnostic x-rays: estimates for the UK and 14 other countries. Lancet 2004 Jan 31; 363(9406): 345–51CrossRef Berrington De Gonzales A, Darby S. Risk of cancer form diagnostic x-rays: estimates for the UK and 14 other countries. Lancet 2004 Jan 31; 363(9406): 345–51CrossRef

go back to reference Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII — phase 2. Washington, DC: National Academies Press, 2001 Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII — phase 2. Washington, DC: National Academies Press, 2001

go back to reference Brenner DJ, Elliston CD. Estimated radiation risks potentially associated with full-body CT screening. Radiology 2004 Sep; 232(3): 735–8PubMedCrossRef Brenner DJ, Elliston CD. Estimated radiation risks potentially associated with full-body CT screening. Radiology 2004 Sep; 232(3): 735–8PubMedCrossRef

go back to reference Direttiva 971431Euratom del Consiglio del 30 giugno 1997 riguardante la protezione sanitaria delle persone contro i pericoli delle radiazioni ionizzanti connesse a esposizioni mediche. Gazzetta ufficiale n. L 180 del 09/07/1997: 22–7 Direttiva 971431Euratom del Consiglio del 30 giugno 1997 riguardante la protezione sanitaria delle persone contro i pericoli delle radiazioni ionizzanti connesse a esposizioni mediche. Gazzetta ufficiale n. L 180 del 09/07/1997: 22–7

go back to reference Dewey M, Diibel HP, Schink T, et al. Head-to-head comparison of multislice computed tomography and exercise electrocardiography for diagnosis of coronary artery disease. Eur Heart J 2007 Oct; 28(20): 2485–90PubMedCrossRef Dewey M, Diibel HP, Schink T, et al. Head-to-head comparison of multislice computed tomography and exercise electrocardiography for diagnosis of coronary artery disease. Eur Heart J 2007 Oct; 28(20): 2485–90PubMedCrossRef

go back to reference Picano E. The alternative ischemic cascade in coronary microvascular disease. Cardiologia 1999 Sep; 44(9): 791–5PubMed Picano E. The alternative ischemic cascade in coronary microvascular disease. Cardiologia 1999 Sep; 44(9): 791–5PubMed

go back to reference de Simone G, Parati G. Imaging techniques for non-invasive assessment of coronary heart disease in hypertension: value of an integrated approach. J Hypertens 2001 Apr; 19(4): 679–82PubMedCrossRef de Simone G, Parati G. Imaging techniques for non-invasive assessment of coronary heart disease in hypertension: value of an integrated approach. J Hypertens 2001 Apr; 19(4): 679–82PubMedCrossRef

go back to reference Massie BM, Szlachcic Y, Tubau JF, et al. Scintigraphic and electrocardiographic evidence of silent coronary artery disease in asymptomatic hypertension: a case-control study. J Am Coll Cardiol 1993 Nov 15; 22(6): 1598–606PubMedCrossRef Massie BM, Szlachcic Y, Tubau JF, et al. Scintigraphic and electrocardiographic evidence of silent coronary artery disease in asymptomatic hypertension: a case-control study. J Am Coll Cardiol 1993 Nov 15; 22(6): 1598–606PubMedCrossRef

go back to reference Neal B, MacMahon S, Chapman N, et al., for the Blood Pressure Lowering Treatment Trialists’ Collaboration. Effect of Angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955–64CrossRef Neal B, MacMahon S, Chapman N, et al., for the Blood Pressure Lowering Treatment Trialists’ Collaboration. Effect of Angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955–64CrossRef

go back to reference Alderman MH. Joint National Committee (JNC) 7: brief summary and critique. Clin Exp Hypertens 2004 Oct–Nov; 26(7-8): 753–61PubMedCrossRef Alderman MH. Joint National Committee (JNC) 7: brief summary and critique. Clin Exp Hypertens 2004 Oct–Nov; 26(7-8): 753–61PubMedCrossRef

go back to reference Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993 Oct; 22(4): 1111–6PubMedCrossRef Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993 Oct; 22(4): 1111–6PubMedCrossRef

go back to reference Kjeldsen SE, Dahlof B, Devereux RB, et al., for the Losartan Intervention for Endpoint Reduction (LIFE) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint reduction in hypertension (LIFE) substudy. JAMA 2002; 288(12): 1491–8PubMedCrossRef Kjeldsen SE, Dahlof B, Devereux RB, et al., for the Losartan Intervention for Endpoint Reduction (LIFE) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint reduction in hypertension (LIFE) substudy. JAMA 2002; 288(12): 1491–8PubMedCrossRef

go back to reference Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991 Jun; 83(6): 1849–65PubMedCrossRef Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991 Jun; 83(6): 1849–65PubMedCrossRef

go back to reference Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenonel enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003 Oct 14; 108(15): 1831–8PubMedCrossRef Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenonel enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003 Oct 14; 108(15): 1831–8PubMedCrossRef

go back to reference ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97

go back to reference Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999 Sep 27; 159(17): 2004–9PubMedCrossRef Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999 Sep 27; 159(17): 2004–9PubMedCrossRef

go back to reference Gibbons RJ, Abrams J, Chatterjee K, et al., for the American College of Cardiology, American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: summary article — a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003 Jan 1; 41(1): 159–68PubMedCrossRef Gibbons RJ, Abrams J, Chatterjee K, et al., for the American College of Cardiology, American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: summary article — a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003 Jan 1; 41(1): 159–68PubMedCrossRef

go back to reference Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999 Sep; 34(3): 890–911PubMedCrossRef Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999 Sep; 34(3): 890–911PubMedCrossRef

go back to reference Yusuf S, Pfeffer MA, Swedberg K, et al., for the CHARM Investigators and Committees. Candesartan cilexitil in Heart failure: Assessment of Reduction in morbidity and Mortality (CHARM) Preserved Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386): 777–81PubMedCrossRef Yusuf S, Pfeffer MA, Swedberg K, et al., for the CHARM Investigators and Committees. Candesartan cilexitil in Heart failure: Assessment of Reduction in morbidity and Mortality (CHARM) Preserved Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386): 777–81PubMedCrossRef

go back to reference Pitt B, Remme W, Zannad F, et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published erratum appears in N Engl J Med 2003 May 29; 348 (22): 22711]. N Engl J Med 2003 Apr 3; 348(14): 1309–21PubMedCrossRef Pitt B, Remme W, Zannad F, et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published erratum appears in N Engl J Med 2003 May 29; 348 (22): 22711]. N Engl J Med 2003 Apr 3; 348(14): 1309–21PubMedCrossRef

go back to reference Messerli FH, Michalewicz L. Hypertensive heart disease, ventricular dysrhythmias, and sudden death. Adv Exp Med Biol 1997; 432: 263–72PubMedCrossRef Messerli FH, Michalewicz L. Hypertensive heart disease, ventricular dysrhythmias, and sudden death. Adv Exp Med Biol 1997; 432: 263–72PubMedCrossRef

go back to reference Bmne S, Gonska BD, Fleischmann C, et al. Prevalence of late ventricular potentials in hypertensive patients. J Cardiovasc Pharmacol 1991; 17Suppl. 2: S146–7 Bmne S, Gonska BD, Fleischmann C, et al. Prevalence of late ventricular potentials in hypertensive patients. J Cardiovasc Pharmacol 1991; 17Suppl. 2: S146–7

go back to reference Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998 Feb 9; 158(3): 229–34PubMedCrossRef Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998 Feb 9; 158(3): 229–34PubMedCrossRef

go back to reference Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998 Oct 16; 82(8A): 2N–9NPubMedCrossRef Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998 Oct 16; 82(8A): 2N–9NPubMedCrossRef

go back to reference Fuster V, Rydén LE, Cannom DS, et al. American College of CardiologylAmerican Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology1 American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [published erratum appears in Circulation 2007 Aug 7; 116 (6): e1381. Circulation 2006 Aug 15; 114(7): e257–354PubMed Fuster V, Rydén LE, Cannom DS, et al. American College of CardiologylAmerican Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology1 American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [published erratum appears in Circulation 2007 Aug 7; 116 (6): e1381. Circulation 2006 Aug 15; 114(7): e257–354PubMed

go back to reference Pringle SD, Dunn FG, Macfarlane PW, et al. Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1992 Apr 1; 69 (9): 913–7 Pringle SD, Dunn FG, Macfarlane PW, et al. Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1992 Apr 1; 69 (9): 913–7

go back to reference Dunn FG, Pfeffer A. Left ventricular hypertrophy in hypertension. N. Engl J Med 1999 Apr 22; 340(16): 1279–80PubMedCrossRef Dunn FG, Pfeffer A. Left ventricular hypertrophy in hypertension. N. Engl J Med 1999 Apr 22; 340(16): 1279–80PubMedCrossRef

go back to reference Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998 Nov; 32(5): 1454–9PubMedCrossRef Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998 Nov; 32(5): 1454–9PubMedCrossRef

go back to reference Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998 Nov 24; 98(21): 2334–51PubMedCrossRef Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998 Nov 24; 98(21): 2334–51PubMedCrossRef

go back to reference Goldberger JJ. Treatment and prevention of sudden cardiac death: effect of recent clinical trials. Arch Intern Med 1999 Jun 28; 159(12): 1281–7PubMedCrossRef Goldberger JJ. Treatment and prevention of sudden cardiac death: effect of recent clinical trials. Arch Intern Med 1999 Jun 28; 159(12): 1281–7PubMedCrossRef

go back to reference Alfakih K, Reid S, Hall A, et al. The assessment of left ventricular hypertrophy in hypertension. J Hypertens 2006 Jul; 24(7): 1223–30PubMedCrossRef Alfakih K, Reid S, Hall A, et al. The assessment of left ventricular hypertrophy in hypertension. J Hypertens 2006 Jul; 24(7): 1223–30PubMedCrossRef